MOUNTAIN VIEW, Calif., Oct. 26 /PRNewswire/ — Based on its
recent analysis of the prostate cancer diagnosis market, Frost
& Sullivan recognizes Hybridyne Technologies, Inc. with the
2010 North American Frost & Sullivan Award for Technology
Innovation of the Year.
(Logo: http://photos.prnewswire.com/prnh/20081117/FSLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
ProxiScan™, recently approved by the FDA, is based on the
compact cadmium-zinc-telluride (CZT) detector, which is the core
enabling component for creating high resolution images.
ProxiScan™ is unique because it differs from traditional
scintillator-based SPECT gamma cameras by offering much higher
spatial resolution. It emerges as a technology that can lead to a
more accurate and timely diagnosis and vastly improve upon the
treatment strategies used for patients, leading to improved cancer
care.
“This technology has the distinct advantages of being compact
and less costly, while offering better image quality within a
smaller field of view,” explains Frost & Sullivan Industry
Analyst Sangeetha Prabakar. “Not only does it provide effective and
more accurate localization of cancer at an earlier stage, the
device’s compactness also allows more accurate imaging by targeting
the desired imaging area.”
Because of its compact design, ProxiScan™ can be used for
trans-rectal imaging and intra-body cavity measurements, which were
originally not possible with conventional gamma cameras. With
ProxiScan™, the working distance between the gamma camera and
prostate gland is greatly minimized. This allows urologists to
obtain much better images of abnormal tissue with smaller amounts
of the injected radioactive tracer.
“ProxiScan™’s spectrometer-mode imaging capabilities,
c
‘/>”/>
